65657-53-6

Usage

Carbonyl chloride derivative

1H-Benzimidazole The compound is derived from 1H-benzimidazole, which is a heterocyclic compound with a benzene ring fused to an imidazole ring, by attaching a carbonyl chloride group.

Heterocyclic compound

Benzene ring fused to an imidazole ring The structure of the compound consists of a benzene ring and an imidazole ring, which are both heterocyclic (containing atoms other than carbon and hydrogen) and fused together.

Utilized in organic synthesis

Key intermediate 1H-Benzimidazole-1-carbonyl chloride, 2,3-dihydro-2-oxo(9CI) is used as a crucial intermediate in the synthesis of various organic compounds.
5. Production of pharmaceuticals, agrochemicals, and other fine chemicals 1H-Benzimidazole-1-carbonyl chloride, 2,3-dihydro-2-oxo- (9CI) serves as a building block in the production of various chemicals, including pharmaceuticals, agrochemicals, and other specialty chemicals.

Versatile building block

Reactivity and ability to undergo various chemical transformations The compound is highly reactive and can participate in a wide range of chemical reactions, making it a valuable building block for synthesizing different compounds.

Potential applications in medicinal chemistry and drug development

Benzimidazole scaffold's pharmacological activities The benzimidazole core structure of the compound may have therapeutic potential due to its pharmacological properties, making it a candidate for further research in drug development.

Downstream Products

• 123259-13-2 N-(endo-8-phenylmethyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxamide 
• 123258-83-3 2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide 
• 123258-84-4 Itasetron 
• 123259-02-9 2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid 1-aza-bicyclo[2.2.2]oct-4-yl ester; hydrochloride 

Relevant academic research and scientific papers

Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists

New pharmacologically active benzimidazoline-2-oxo-1-carboxylic acid derivatives which are 5-HT receptor antagonists useful as antiemetic agents and as gastric prokinetic agents of the following formula: STR1wherein R is hydrogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; R 1 is hydrogen; R 2 is hydrogen, halogen or C 1-6 alkoxy; Y is oxygen or N--R 3 in which R 3 is hydrogen; A is a group selected from: STR2wherein p is 1; r is 0, 2 or 3: R 4 is hydrogen; R 5 is hydrogen, C 1-6 alkyl, or R 5 is a group of the formula --CR 6 =N--R 7 wherein R 6 is hydrogen, C 1-4 alkyl or amino and R 7 is hydrogen or C 1-6 alkyl; or a pharmaceutically acceptable acid addition salt thereof.The processes for the preparation of the compounds of formula (I) as well as pharmaceutical compositions contained in them are also described.

New benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists

New pharmacologically active benzimidazoline-2-oxo-1-carboxylic acid derivatives which are 5-HT receptor antagonists useful as antiemetic agents and as gastric prokinetic agents of the following formula: wherein R represents a hydrogen atom, C1 6 alkyl, C1 6 alkenyl or C1 6 alkynil; R1 and R2 may be at the same time or not a hydrogen atom, halogen, trifluoromethyl, C1 6 alkyl, C1 6 alkoxy, C1 6 alkylthio, C1 6 acyl, carboxyl, C1 6 alkoxycarbonyl, hydroxy, nitro, amino optio-nally C1 4 alkyl N-mono or di-substituted, C1 6 acylamino, C1 6 alkoxy-carbonylamino, carbamoyl optionally C1 4 alkyl N-mono or di-substitu-ted, cyano, C1 6alkylsulphinyl, C1 6 alkylsulphonyl, amino sulphonyl optionally C1 4 alkyl N-mono or di-substituted, C1 4 alkyl N-mono or di-substituted aminosulphonylamino, aminosulphonylamino; Y is oxygen or is N - R3 in which R3 is a hydrogen, a C1 6 alkyl or optionally substituted by one or more C1 6 alkoxy benzyl; A is a group selected from: wherein p is 0, 1; r is 0, 1, 2, 3; R4 is hydrogen atom or a C1 4 alkyl; R5 is a hydrogen atom, C1 6 alkyl, C3 8 cycloalkyl, C3 8 cycloalkyl C1 4 alkyl,substituted phenyl C1 4 alkyl or R5 is a group of formula wherein R6 is hydrogen atom, C1 4 alkyl or an amino group and R7 is hydrogen atom or C1 6 alkyl, tautomers thereof and acid addition salts of the aforesaid compounds. The processes for the preparation of the compounds of formula (I) as well as pharmaceutical compositions containing them are also described.